AI Summary
✦ ClarthaRainbow Children’s Medicare is an Indian hospital chain focused on paediatric, obstetrics, and gynaecology healthcare. Rainbow Children’s Hospital drives paediatric revenue through intensive care, multispecialty treatment, and quaternary services including transplantation. Birthright contributes women’s healthcare revenue through complex obstetrics, fetal care, fertility support, and gynaecology. Consolidated June 2026 sales rose 33.2% year-on-year, while Mumbai expansion could broaden capacity and future growth. Revenue grew 12.2%, with profit increasing 14.3% and margins remaining stable. ROE is unavailable, while debt-to-equity of 53.56 indicates substantial leverage that can amplify reported shareholder returns and financial risk. At 54.6 times earnings, the stock appears rich relative to its 12.2% revenue growth, despite recent sales acceleration. Expansion execution, capital intensity, and whether Mumbai reaches targeted utilisation remain key open questions.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 14 analysts
Fundamentals
Fundamentals institutional score is 63 using growth durability 63.3.
Valuation
Valuation institutional score is 36 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 73 using mean target upside 14.1%; dispersion penalty 10.3; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 59 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. analyst consensus provide support, while valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 17.3% above historical median. Valuation is declining — currently in the strongly overvalued zone (z-score: +1.56). Confidence: 88%.
Live forward EPS implies next-12-month EPS of ₹39.56. Applying the stock's normalized valuation corridor produces a fair range of ₹1,696.73 to ₹1,987.10, with base value near ₹1,862.88 (+21.1% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹39.56
Forward P/E
38.9x
Base Fair Value
₹1,862.88
Fair Range
₹1,696.73 - ₹1,987.10
Upside To Base
+21.1%
Estimate Source
Live forward EPS
Growth Estimate
+13.3%
5Y Average
41.30
Current
55.24
Overvalued
50.23
Undervalued
42.89
5Y Average
20.78
Current
27.48
Overvalued
24.74
Undervalued
17.86
5Y Average
6.49
Current
8.58
Overvalued
7.72
Undervalued
5.58
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.8x Undervalued | -31% vs avg | +10.2% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 55.8x Undervalued | -35% vs avg | +11.3% |
FORTIS HEALTHCARE LTD FORTISHospitals & Diagnostic Centres | +17.5% | 11.0% | 68.7x Undervalued | -20% vs avg | +3.7% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 45.3x Undervalued | -47% vs avg | +6.8% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 71.4x Undervalued | -17% vs avg | +4.9% |
NEPHROCARE HEALTH SERV L NEPHROPLUSHospitals & Diagnostic Centres | +21.2% | 7.7% | 85.9x Fair | 0% vs avg | +47.3% |
ASTER DM QUALITY CARE LTD ASTERDMHospitals & Diagnostic Centres | +21.6% | 6.5% | 140.5x Premium | +64% vs avg | +47.9% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 160.4x Premium | +87% vs avg | +11.6% |
RAINBOW CHILDRENS MED LTD trades at a discount (54.6x vs peer avg 85.8x), suggesting potential undervaluation relative to the Hospitals & Diagnostic Centres cohort. Peers include METROPOLIS HEALTHCARE LTD, JUPITER LIFE LINE HOSP L, FORTIS HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹411 CrJun 2026Latest net profit
₹53 CrJun 2026Latest EPS
₹5.19Jun 2026Net margin
28.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 270 | 319 | 322 | 326 | 315 | 404 | 382 | 354 | 335 | 408 | 394 | 408 | 411 |
| Expenses + | 188 | 204 | 208 | 223 | 225 | 260 | 251 | 243 | 235 | 268 | 264 | 279 | 296 |
| Operating Profit | 83 | 114 | 114 | 103 | 90 | 143 | 130 | 111 | 100 | 141 | 131 | 129 | 115 |
| OPM % | 31% | 36% | 35% | 32% | 29% | 36% | 34% | 31% | 30% | 34% | 33% | 32% | 28% |
| Other Income + | 8 | 9 | 8 | 12 | 11 | 11 | 13 | 14 | 19 | 8 | 11 | 4 | 13 |
| Interest | 14 | 13 | 14 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 18 | 19 | 19 |
| Depreciation | 24 | 25 | 26 | 31 | 32 | 33 | 34 | 33 | 33 | 33 | 35 | 36 | 38 |
| Profit before tax | 53 | 86 | 83 | 68 | 52 | 104 | 92 | 75 | 69 | 98 | 88 | 78 | 71 |
| Tax % | 25% | 25% | 26% | 26% | 25% | 25% | 27% | 27% | 25% | 26% | 26% | 24% | 25% |
| Net Profit + | 39 | 64 | 61 | 50 | 39 | 77 | 67 | 55 | 52 | 73 | 66 | 59 | 53 |
| EPS in Rs | 3.87 | 6.30 | 6.02 | 4.97 | 3.82 | 7.62 | 6.60 | 5.37 | 5.09 | 7.20 | 6.48 | 5.84 | 5.19 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript